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ABSTRACT
Introduction: ENDURE (ClinicalTrials.gov
identifier, NCT00856284), a multicenter,
double-blind, active-controlled study of 2639
patients with uncontrolled type 2 diabetes
mellitus (T2DM), found that metformin in
combination with alogliptin (12.5 and 25 mg
doses), when compared to standard add-on
therapy (sulfonylurea, SU), exerted sustained
antihyperglycemic effects over 2 years. This
economic analysis of ENDURE aimed to
quantify the relationship between increased
glycemic durability and cost-effectiveness of
alogliptin in the UK clinical setting, and
communicate its sustained glycemic benefit in
economic terms.
Methods: Using baseline characteristics and
treatment effects from the ENDURE trial
population, between-group cost-effectiveness
analyses compared the combined use of
metformin and alogliptin (MET ? ALO12.5/25)
in patients with inadequately controlled
T2DM, as an alternative to metformin and SU
(MET ? SU). In scenario analyses, an intragroup
cost-effectiveness analysis compared
MET ? ALO12.5/25 with MET ? SU; a
between-group cost-effectiveness analysis also
compared MET ? ALO12.5/25 versus MET ? SU
within a subpopulation of patients who
achieved HbA1c control (\7.5%) at 2 years on
study drug.
Results: Compared with baseline profiles of
patients, combination therapies with
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alogliptin or SU were associated with
improvements in length and quality of life
and were cost-effective at established norms.
Despite increased drug acquisition costs,
alogliptin at 12.5 mg and 25 mg doses resulted
in greater predicted lifetime quality-adjusted
life year (QALY) gains with associated
incremental cost-effectiveness ratios (ICERs) of
£10,959/QALY and £7217/QALY compared to
SU, respectively.
Conclusion: The ENDURE trial and the present
cost-effectiveness analysis found that the
glycemic durability of alogliptin therapy was
associated with improved long-term patient
outcomes, QALY gains, and ICERs that were
cost-effective when evaluated against standard
threshold values. Alogliptin therefore represents
a cost-effective treatment alternative to SU as
add-on therapy to metformin in patients with
poorly managed T2DM.
Funding: Takeda Development Centre Europe
Ltd.
Keywords: Alogliptin; Cost-effectiveness
analysis; Glycemic durability; Sulfonylurea;
Second-line therapy; Type 2 diabetes mellitus
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a chronic
metabolic disorder that imposes major social
and economic burdens on public health in the
UK. In addition to the direct healthcare costs
associated with managing T2DM, the societal
and productivity consequences of T2DM also
incur significant indirect costs. In 2010–11, it
was estimated that T2DM affected 3.4 million
adults in the UK, the cost of which exceeded
£21.7 billion [1]. This was made up of £13
billion in indirect expenses and £8.7 billion in
direct healthcare costs [1], which account for up
to 10% of all NHS expenditure [2]. Economic
projections have hypothesized that the
prevalence of T2DM in the UK will rise to 5.6
million adults in 2035–36, and will incur direct
NHS costs exceeding £15.1 billion. The indirect
costs of the morbidity and mortality associated
with T2DM were also projected to rise, to £20.5
billion by 2035–36 [1].
More than 75% of NHS expenditure on
T2DM is related to the costs of treating the
complications of T2DM, rather than the
ongoing management of the condition itself
[1]. These complications include cardiovascular
events, neuropathy, renal disorders, visual
impairment, and amputations, many of which
are avoidable consequences of suboptimal
glycemic control. The National Institute for
Health and Care Excellence (NICE)
recommends that T2DM therapy ought to
lower glycated hemoglobin A1c (HbA1c) levels
to 48 mmol/mol (6.5%) [2]; however,
approximately 30% of patients fail to reach
and maintain this goal [3]. Effective
management of T2DM, through improvements
to current treatment strategies, has the
potential to reduce adverse micro- and
macrovascular complications, and their
associated burden.
Clinical guidelines for the management of
T2DM initially advocate metformin, in
combination with diet and lifestyle changes
[2, 4]. However, given the progressive nature of
T2DM due to declining beta cell function,
long-term glycemic management is invariably
associated with the requirement for therapy
escalation [5, 6]. In patients suboptimally
controlled on metformin monotherapy,
sulfonylurea (SU) is a common second-line
treatment option [2]. Whilst combination
therapy with drugs of this class is associated
with significant reductions in HbA1c, SUs are
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additionally associated with weight gain and an
increased risk of hypoglycemia [7]. The risk of
these adverse events is further exacerbated
when secondary treatment failure progressively
necessitates the addition of further oral
therapies and/or insulin initiation [6].
Inhibitors of dipeptidyl peptidase-4 (DPP-4)
exert antihyperglycemic effects in T2DM,
without increased risk of weight gain or
hypoglycemic events [7]. Alogliptin is a
selective inhibitor of DPP-4, and its
antidiabetic efficacy in monotherapy and
combination therapy has been established in
clinical studies over 1 year [8–10]. To investigate
the long-term glycemic durability of alogliptin,
ENDURE (Efficacy and safety of alogliptin plus
metformin compared to glipizide plus
metformin in subjects with type 2 diabetes
mellitus; ClinicalTrials.gov identifier,
NCT00856284) was a multicenter,
double-blind, active-controlled trial that
compared alogliptin with an SU (glipizide) in
combination with metformin in poorly
managed T2DM over 2 years [11]. The trial
found that, in patients with inadequate
glycemic control following stable-dose
metformin treatment, combination therapy
with alogliptin (12.5 and 25 mg once daily)
was associated with significant improvements
in HbA1c, fasting plasma glucose, and the
incidence of weight gain, hyperglycemic
rescue, and hypoglycemic events over 2 years
[11]. In a post hoc analysis of ENDURE, a
significantly greater proportion of the
alogliptin cohort achieved the composite
endpoint of glycemic control, without weight
gain or hypoglycemia [12].
Although ENDURE demonstrated the clinical
effectiveness of alogliptin compared to SU as a
second-line therapy for T2DM, further studies
are required to determine whether its durability
benefits may translate to improved
cost-effectiveness. The present economic
analysis of ENDURE aimed to evaluate the
relative cost-effectiveness of alogliptin
compared to SU in the UK clinical setting.
METHODS
Patient Population
Baseline characteristics and treatment effects
were sourced from the ENDURE trial population
(N = 2639) [11]. Patients were randomized to
receive 12.5 mg alogliptin once daily (n = 880),
25 mg alogliptin once daily (n = 885), or 5 mg
glipizide once daily (n = 874) for 104 weeks, in
combination with at least 1500 mg open-label
metformin once daily (or maximum tolerated
dose). The model cohort was considered to be
representative of UK patients who would be
eligible to receive alogliptin as part of a UK
treatment strategy.
Cost-Effectiveness Model
Economic analysis of ENDURE trial data was
performed using the widely published and
validated IMS Core Diabetes Model (CDM), a
generic (non-product-specific) computer
simulation model used to predict the
long-term incidence of adverse events and the
economic consequences of interventions in the
management of T2DM [13].
The CDM is a fixed-time increment
stochastic model comprised of 17 interrelated
state transition Markov submodels, with each
submodel using time, state, and
patient-dependent probabilities. Monte Carlo
simulations are performed at the individual
patient level using tracker variables to
accommodate complex interactions between
individual complication submodules. The
CDM simulates diabetes-related micro- and
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macrovascular complications (angina,
myocardial infarction, congestive heart failure,
stroke, peripheral vascular disease, diabetic
retinopathy, macular edema, cataract,
hypoglycemia [nocturnal, severe, and
symptomatic], ketoacidosis, lactic acidosis,
nephropathy and end-stage renal disease,
neuropathy, foot ulcer, and amputation),
cardiovascular, and non-specific mortality. It
accommodates direct and indirect costs, adjusts
for quality of life, and performs
cost-effectiveness and cost–utility analyses.
Separate transition probabilities and
management strategies for type 1 and type 2
diabetes are utilized within the model, and
source data for model parameters are obtained
from a broad range of published clinical and
epidemiological studies, predominantly the
Diabetes Control and Complications Trial
(DCCT) [14] and Framingham studies [15] for
type 1 diabetes and UKPDS studies [16, 17] for
T2DM.
Patient progression through the model is
determined by baseline clinical and
demographic characteristics. The progression
of T2DM is modelled using annual time
increments. As the simulation progresses,
time-dependent risk factors are updated or
modified according to a therapy change,
thereby altering the likelihood of event
occurrence.
Analyses
Within each analysis, a cohort of 1000 patients
was simulated for each treatment arm based on
the baseline profile and treatment effect
adjusted for distributions in the deviation of
CDM inputs. Each patient was simulated for a
lifetime time horizon (excluding where model
inputs were fluctuating as part of a sensitivity
analysis) up to a maximum of 50 years on a
yearly cycle. Discount rates for both cost and
utilities were set to 3.5%.
Costs were adjusted for inflation (where
necessary), set against 2015 using the hospital
and community health services (HCHS) index
compiled by the Personal Social Services
Research Unit (PSSRU) [18]. The annual cost of
each regimen was input into the CDM as an
annual cost encompassing both the treatment
and consumables (test strips, lancets, and
needles) required to administer and manage the
treatment. The treatment and consumables were
calculated using both the daily cost obtained
from the latest Monthly Index of Medical
Specialties (MIMS) [19] and daily usage
guidelines for all individual drug regimens and
consumables obtained from either the ENDURE
studyprotocol [11] or daily usage guidelines from
NICE [2]. Where relevant, an average cost of all
relevant products was applied unless explicitly
defined within the treatment arm (including
metformin, alogliptin, and glipizide). Additional
complication specific costs and overall utility
consequences were applied on a per cycle basis
based on the predicted occurrence of
diabetes-related complications. All utilities and
disutility rates were sourced from relevant
literature of patients with T2DM (see appendix
in the Supplementary Material). Modelled costs
and utilities are provided in Tables S1–S8 in the
Supplementary Material.
Across all analyses, CDM input data for the
baseline cohort profile and treatment effect
were sourced from published trial data [11]
supplemented with validated patient level
ENDURE data where required. The baseline
profiles used are presented in Table 1; the
treatment effects for both the overall
population and subpopulation of patients with
HbA1c less than 7.5% at week 104 that were
input into the CDM are presented in Tables 2
and 3, respectively.
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Base Case Analyses
The base case analysis considered the combined
use of metformin and alogliptin
(MET ? ALO12.5/25) in patients with
inadequately controlled T2DM, as an
alternative to metformin and glipizide
(MET ? SU). In line with UK guidelines,
therapy intensification occurred when HbA1c
reached 7.5%; at this point patients were
escalated to insulin therapy: metformin and
neutral protamine Hagedorn insulin
(MET ? NPH) [2].
Probabilistic and Deterministic Sensitivity
Analyses
Additional analyses were performed for the base
case including both probabilistic and a
deterministic sensitivity analysis. For the
probabilistic sensitivity analysis, 1000 runs
were performed in which input parameters
were sampled using the CDM’s default
distribution; for the deterministic sensitivity
analysis, model inputs were fluctuated (10-
and 20-year time horizons; complication costs
±20%; utilities ±20%; discount rates (costs/




Scenario analyses assessed within-group
comparisons using treatment arm-specific
baseline profiles: MET ? SU with no treatment
effect versus MET ? SU with treatment effect;
MET ? ALO12.5 with no treatment effect versus
MET ? ALO12.5 with treatment effect;
MET ? ALO25 with no treatment effect versus
MET ? ALO25 with treatment effect.
ScA-2
A secondary scenario analysis replicated the
base case simulations using a subpopulation of
patients who achieved an HbA1c of 7.5% or less
at 2 years, in line with NICE guidelines [2].
Compliance with Ethics Guidelines
This study was based on a previously conducted
trial, and does not involve any new studies of




The base case economic evaluation compared
alogliptin (12.5 and 25 mg doses) to SU, as
add-on therapies to metformin (Table 4, Fig. 1).
Treatment with alogliptin 12.5 mg was
estimated to incur additional total costs
(£1131) but gains in quality-adjusted life years
(0.103 QALYs) and life expectancy (0.044 years).
The additional total costs were driven by
increased drug acquisition costs (£1399),
which were partly offset by a reduction in
complication costs (£263) from fewer
predicted events. The largest cost offset in the
analysis was attributable to a reduction in the
incidence of CVD. Treatment with alogliptin
12.5 mg compared with SU was associated with
an incremental cost-effectiveness ratio (ICER) of
£10,959/QALY.
Treatment with alogliptin 25 mg was
estimated to incur additional total costs
(£1012) but gains in QALYs (0.140) and life
expectancy (0.081 years). The additional total
costs were driven by increased drug acquisition
costs (£1421), which were partly offset by a
reduction in complication costs (£382) from
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Table 4 Base case event rate and economic analysis of alogliptin as a second-line antidiabetic therapy
MET 1 SU MET 1 ALO12.5 MET 1 ALO25
Macrovascular complications (cumulative incidence %)
CHF death 39.48 40.46 40.80
CHF event 15.72 15.23 15.19
PVD onset 19.26 19.07 18.79
Angina 13.72 13.39 13.06
Diabetes mortality 26.97 26.73 26.81
Stroke event 7.66 7.64 7.53
Event fatality 33.36 32.64 32.21
MI event 18.42 17.85 17.63
Microvascular complications (cumulative incidence %)
Background diabetic retinopathy 29.62 29.29 29.35
Proliferative diabetic retinopathy 2.56 2.49 2.48
Macular edema 25.47 25.14 25.19
Severe vision loss 12.83 12.55 12.56
Cataract 13.09 13.05 13.08
Microalbuminuria 41.25 41.00 40.88
Gross proteinuria 14.80 14.59 14.48
ESRD 4.86 4.78 4.66
Nephropathy (death) 0.00 0.00 0.00
Ulcer 41.9 41.52 41.57
Recurrent ulcer 89.6 88.72 88.88
Amputation due to ulcer 19.53 19.34 19.43
Amputation due to recurrent ulcer 13.41 13.30 13.38
Neuropathy 72.8 72.53 72.49
Absolute results (discounted)
Total cost (£) 27,835 28,966 28,847
Treatment 6644 8043 8065
Management 462 463 465
CVD 7450 7358 7259
ESRD 1245 1186 1164
Ulcer/amputation/neuropathy 10,130 10,038 10,043
Eye 1851 1831 1828
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fewer predicted events. The largest cost offset in
the analysis was attributable to a reduction in
the incidence of CVD. Treatment with
alogliptin 25 mg compared with SU was
associated with an ICER of £7217/QALY.
Results of the probabilistic sensitivity
analysis support the base case results and give
an indication as to the likelihood of
cost-effectiveness at various willingness to pay
thresholds. ICER scatterplots (Figs. 2, 3)
demonstrate that in the comparison of
alogliptin 12.5 mg and SU, alogliptin 12.5 mg
was cost-effective at a threshold of £30,000/
QALY with a probability of cost-effectiveness of
67.6%. Similarly, in the analysis of alogliptin
25 mg and SU, the probability of
cost-effectiveness of alogliptin 25 mg was
77.1% at a £30,000/QALY willingness to pay
threshold.
Results of the deterministic sensitivity
analysis are reported in Table 5. The
cost-effectiveness of alogliptin 12.5 and 25 mg
was insensitive to change in key model input
parameters and remained cost-effective
compared to SU across deterministic sensitivity
analyses. For alogliptin 12.5 mg, ICERs across
sensitivity analyses ranged from £6932/QALY to
£24,143/QALY (base case ICER £10,959/QALY).
For alogliptin 25 mg, ICERs across sensitivity
analyses ranged from £4225/QALY to £19,056/
QALY (base case ICER £7217/QALY). ICERs
improved with increased time horizon driven
by increased accumulation of QALYs. However,
even at a 10-year time horizon, alogliptin was
cost-effective compared with SU with ICERs less
than £20,000/QALY at 12.5 and 25 mg doses.
Scenario Analysis (ScA)
ScA-1
A within-arm cost-effectiveness analysis was
undertaken for each treatment group: SU,
alogliptin 12.5 mg, and alogliptin 25 mg. In
each analysis, patient baseline profiles were
Table 4 continued
MET 1 SU MET 1 ALO12.5 MET 1 ALO25
Hypoglycemia 0 0 0
Total LE 14.833 14.878 14.914
Total QALY 9.720 9.824 9.861
Between groups analysis (MET ? SU vs MET ? ALO12.5/25)
Incremental cost 1131 1012
Incremental LE 0.044 0.081
Incremental QALY 0.103 0.14
ICER (cost/LE) 25,588 12,476
ICER (cost/QALY) 10,959 7217
CE? (£30,000 ICER) 67.6 77.1
MI myocardial infarction, CVD cardiovascular disease, ESRD end-stage renal disease, LE life expectancy, QALY
quality-adjusted life year, ICER incremental cost-effectiveness ratio, CE? probability of cost-effectiveness
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Fig. 1 Relationship between sustained antihyperglycemic efﬁcacy (HbA1c) and cost-effectiveness of alogliptin 12.5 mg and
25 mg vs SU ([adapted from [11])
Fig. 2 Incremental cost-effectiveness ratio scatterplot (SU vs alogliptin 12.5 mg)
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compared to 12-month profiles (12 and
24 months for HbA1c), to evaluate the
cost-effectiveness of each treatment allocation.
Treatment with SU was estimated to incur
higher total costs (£2194) but gains in QALYs
(0.211) and life expectancy (0.291 years) as an
add-on to metformin. The higher total costs
were driven by an increase in drug acquisition
costs, but partly offset by a corresponding
decrease in complication costs from fewer
predicted events. The largest cost components
in the analysis were attributable to the
incidence of ulcer, amputation, and
neuropathy. The addition of an SU to
metformin was associated with an ICER of
£10,398/QALY (Table 6).
Treatment with alogliptin 12.5 mg was
estimated to incur additional total costs
(£3325) but gains in QALYs (0.315) and life
expectancy (0.336 years). The additional total
costs were driven by increased drug acquisition
costs, which were partly offset by a reduction in
complication costs from fewer predicted events.
The largest cost offsets in the analysis were
attributable to CVD and renal disease, and the
incidence of ulcer amputation and neuropathy.
The addition of alogliptin 12.5 mg to
metformin was associated with an ICER of
£10,556/QALY (Table 6).
Treatmentwithalogliptin25 mgwas estimated
to incur additional total costs (£3206) but gains in
QALYs (0.352) and life expectancy (0.372 years).
The additional total costswere drivenby increased
drug acquisition costs, which were partly offset by
a reduction in complication costs from fewer
predicted events. The largest cost offsets in the
analysis were attributable to CVD and renal
disease, and the incidence of ulcer amputation
and neuropathy. The addition of alogliptin 25 mg
to metformin was associated with an ICER of
£9108/QALY (Table 6).
ScA-2
A subgroup economic evaluation was
undertaken of the base case population
(between-arm comparison of SU and
Fig. 3 Incremental cost-effectiveness ratio scatterplot (SU vs alogliptin 25 mg)
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alogliptin), to assess the cost-effectiveness
profile of subjects who maintained a level of
HbA1c at 2 years (104 weeks) of less than 7.5%.
Results of this scenario analysis were similar to
the base case analysis in terms of absolute costs
and health benefits, with ICERs (probability of
cost-effectiveness at £30,000/QALY) of £13,326/
QALY (61.0%) and £6771/QALY (72.4%) for the
comparison of SU and alogliptin 12.5 mg and
25 mg, respectively (Table 7).
DISCUSSION
As a result of both the incidence and increasing
prevalence of T2DM in the UK, the
consequences of suboptimal glycemic control
impose a considerable economic burden on
patients and the NHS. These costs are further
exacerbated when current treatment strategies
lack the glycemic durability required to manage
the progressive nature of the condition. When
Table 5 Deterministic sensitivity analysis results (SU vs alogliptin 12.5 mg and 25 mg)






MET ? ALO12.5 mg
Base case 1131 0.103 10,959
10-year horizon 1297 0.054 24,143
20-year horizon 1109 0.082 13,571
Costs -20% 1184 0.103 11,477
Utilities -20% 1131 0.094 11,993
Costs ?20% 1078 0.103 10,441
Utilities ?20% 1131 0.112 10,098
Discount rate 0% 1121 0.162 6932
Discount rate 7% 1074 0.072 14,961
Duration switch 5 years 1008 0.082 12,252
MET ? ALO25 mg
Base case 1012 0.140 7217
10-year horizon 1201 0.063 19,056
20-year horizon 1000 0.109 9200
Costs -20% 1093 0.140 7799
Utilities -20% 1012 0.125 8101
Costs ?20% 930 0.140 6635
Utilities ?20% 1012 0.155 6515
Discount rate 0% 1022 0.242 4225
Discount rate 7% 978 0.091 10,721
Duration switch 5 years 877 0.120 7306
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compared to standard second-line SU therapy,
the ENDURE trial showed that DPP-4 inhibition
by alogliptin elicited sustained
antihyperglycemic effects, without weight gain
and hypoglycemia, in T2DM patients who had
failed first-line metformin monotherapy
[11, 12].
The present economic analysis of ENDURE
aimed to quantify the relationship between
improved glycemic durability and
Table 6 Intragroup economic analysis of SU, alogliptin 12.5 mg, and alogliptin 25 mg as a second-line antidiabetic therapy
MET 1 SU MET 1 ALO12.5 MET 1 ALO25
Baseline Month 12 Baseline Month 12 Baseline Month 12
Absolute results (discounted)
Total cost (£) 25,641 27,835 25,641 28,966 25,641 28,847
Total LE 14.542 14.833 14.542 14.878 14.542 14.914
Total QALY 9.509 9.720 9.509 9.824 9.509 9.861
Incremental cost 2194 3325 3206
Incremental LE 0.291 0.336 0.372
Incremental QALY 0.211 0.315 0.352
ICER (cost/LE) 7540 9896 8618
ICER (cost/QALY) 10,398 10,556 9108
LE life expectancy, QALY quality-adjusted life year, ICER incremental cost-effectiveness ratio
Table 7 Economic analysis of SU, alogliptin 12.5 mg, and alogliptin 25 mg for HbA1c control (\7.5%) subpopulation
MET 1 SU MET 1 ALO12.5 MET 1 ALO25
Absolute results (discounted)
Total cost (£) 28,688 29,565 29,435
Total LE 14.641 14.663 14.708
Total QALY 9.603 9.688 9.713
Between groups analysis (MET ? SU vs MET ? ALO12.5/25)
Incremental cost 877 746
Incremental LE 0.022 0.068
Incremental QALY 0.066 0.110
ICER (cost/LE) 39,856 11,039
ICER (cost/QALY) 13,326 6771
CE? (£30,000 ICER) 61.0 72.4
LE life expectancy, QALY quality-adjusted life year, ICER incremental cost-effectiveness ratio, CE? probability of
cost-effectiveness
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cost-effectiveness of alogliptin in the UK
clinical setting. This study estimated that in
patients inadequately managed on metformin
monotherapy, the addition of alogliptin (12.5
and 25 mg) was associated with improvements
in length and quality of life and was
cost-effective at established norms. Compared
with baseline profiles of suboptimal
management on metformin monotherapy
(intragroup analysis), combination therapies
with alogliptin or SU were associated with
improvements in length and quality of life
and were cost-effective at established norms.
However, the increased glycemic durability
associated with alogliptin translated to larger
health (QALY) gains predicted across analyses
compared with SU.
Improvements in glycemic control and
durability of antihyperglycemic effects
observed in ENDURE subjects translates to
favorable cost-effectiveness profiles for
alogliptin compared with SU, as add-on
therapies to metformin when analyzed with
an established diabetes model. These
cost-effectiveness conclusions were robust
across a number of scenarios, including
intragroup analyses that confirmed the
cost-effectiveness of the addition of SU and
alogliptin in analyses where patients within
each study arm formed their own control group.
In patients who had HbA1c levels less than
7.5% after 2 years, alogliptin was estimated to
be cost-effective compared with SU at
established norms. In deterministic and
probabilistic sensitivity analyses where the
joint uncertainty in parameter values was
evaluated in terms of its impact on estimates
of cost-effectiveness, base case cost-effectiveness
conclusions were shown to be robust. In
comparison with SU, the probability that
combination therapy with alogliptin (12.5 and
25 mg) was cost-effective was 67.6% and 77.1%
at a willingness to pay threshold of £30,000 per
QALY gained, respectively.
This economic evaluation of ENDURE
provides further evidence supporting the
cost-effectiveness of DPP-4 inhibitors as a
second-line therapy for T2DM [20]. Previous
analyses have indicated that, in T2DM patients
who were no longer responsive to first-line
metformin monotherapy, the addition of
DPP-4 inhibitors was cost-effective compared
to add-on SU [21–25], thiazolidinediones
[25, 26], and insulin [27, 28]. The DPP-4
inhibitors investigated in these studies were
either sitagliptin or saxagliptin; however, a
pharmacoeconomic analysis of antidiabetic
therapies in the Japanese clinical setting found
that alogliptin was a more cost-effective DPP-4
inhibitor than sitagliptin [29]. The ENDURE
trial and its subsequent cost-effectiveness
analysis suggest that the improved efficacy of
second-line alogliptin therapy translated to
improved cost-effectiveness compared to SU in
patients with uncontrolled T2DM.
There are several strengths and limitations
associated with this study. A UK perspective was
adopted for costs and cost-effectiveness settings
(e.g., discount rates), which may affect whether
these findings are relatable to other country
settings. However, the input profiles and
treatment effects from ENDURE were based on
subjects from North and South America,
Europe, Asia, South Africa, Australia, and New
Zealand [11] and are reported transparently
such that country-specific settings for costs
and utilities could be used to replicate this
analysis to inform country-specific
decision-making. Computer modelling in
diabetes is an established and accepted
paradigm, and is used to extrapolate beyond
the trial follow-up period to obtain best
estimates of downstream clinical and
economic outcomes associated with individual
842 Diabetes Ther (2016) 7:825–845
treatments. Nonetheless, a computer
simulation model was used to evaluate how
changes in subjects’ short-term surrogate
outcomes (risk factor profiles) translated to
incidence of diabetes-related complications
and mortality over a lifetime perspective.
Given the lifetime nature of the analysis,
assumptions regarding patient treatment
escalation were made such that patients
escalated (or intensified) to rescue therapy
once their HbA1c value (following initial
treatment-related change) returned to its
starting (or baseline) HbA1c. This is a realistic
assumption that may reflect treatment
intensification practice in the clinical setting.
In the base case analysis, the SU and alogliptin
arms intensified to metformin and NPH insulin
after 7–9 years across analyses; in the modelled
lifetime analysis, discounted average life
expectancy was approximately 14–15 years.
Therefore, the comparison of alogliptin and
SU contains the effects of therapy
intensification for the period of the modelled
time horizon, which should be acknowledged
when interpreting the results. However, as the
therapy intensification profile was applied
equally to each arm, any incremental
differences associated with therapy escalations
should pertain to different times to escalation
which were not substantially different.
CONCLUSION
The use of SU as a second-line indication for
uncontrolled T2DM is associated with weight
gain and hypoglycemic events [7], the risks of
which are further increased when doses are
escalated to combat progressive treatment
failure [6]. In comparison, the ENDURE trial
showed that alogliptin, in combination with
metformin, was associated with improved
glycemic durability, without weight gain and
hypoglycemia, over 2 years [11, 12]. With base
case estimated ICERs of £10,959/QALY and
£7217/QALY, evaluated against commonly
used cost-effectiveness threshold values, this
study demonstrated that alogliptin represents a
cost-effective treatment alternative to SU as
add-on therapy to metformin in patients with
poorly managed T2DM. Cost-effectiveness
conclusions were robust across a number of
evaluated scenarios and in sensitivity analyses.
ACKNOWLEDGEMENTS
Sponsorship for this study and article
processing charges were funded by Takeda
Development Centre Europe Ltd. All named
authors meet the International Committee of
Medical Journal Editors (ICMJE) criteria for
authorship for this manuscript, take
responsibility for the integrity of the work as a
whole, and have given final approval to the
version to be published. Editorial assistance in
the preparation of this manuscript was provided
by Dr Karina Hamilton of HEOR Ltd. Support
for this assistance was funded by HEOR Ltd.
J. Gordon and P. McEwan were involved in the
design, analysis, interpretation, and writing of
the manuscript. J. Puelles was involved in the
design, interpretation, and writing of the
manuscript. M. Hurst was involved in the
design and analysis of the manuscript.
All authors had full access to all of the data in
this study and take complete responsibility for
the integrity of the data and accuracy of the
data analysis.
Disclosures. J. Puelles is an employee of
Takeda Development Centre Europe Ltd.
J. Gordon has served as consultant to and
received research funding from Takeda
Diabetes Ther (2016) 7:825–845 843
Development Centre Europe Ltd in relation to
this study. P. McEwan has served as consultant
to and received research funding from Takeda
Development Centre Europe Ltd in relation to
this study. M. Hurst has served as consultant to
and received research funding from Takeda
Development Centre Europe Ltd in relation to
this study.
Compliance with Ethics Guidelines. This
article is based on previously conducted
studies, and does not involve any new studies
of human or animal subjects performed by any
of the authors.
Data Availability. The datasets analyzed
during the current study were sourced from
and are available in the original trial publication
[11].
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits any noncommer-
cial use, distribution, and reproduction in any
medium, provided you give appropriate credit
to the original author(s) and the source, provide
a link to the Creative Commons license, and
indicate if changes were made.
REFERENCES
1. Hex N, Bartlett C, Wright D, Taylor M, Varley D.
Estimating the current and future costs of type 1
and type 2 diabetes in the UK, including direct
health costs and indirect societal and productivity
costs. Diabet Med. 2012;29:855–62.
2. National Institute for Health and Care Excellence.
Type 2 diabetes in adults: management. NICE
guidelines [NG28]. 2015. https://www.nice.org.uk/
guidance/ng28. Accessed 22 Mar 2016.
3. National Diabetes Audit. National Diabetes Audit
2011-2012. Report 1: Care processes and treatment
targets. 2013. http://www.hscic.gov.uk/catalogue/
PUB12421/nati-diab-audi-11-12-care-proc-rep.pdf.
Accessed 22 Mar 2016.
4. American Diabetes Association. Standards of
Medical Care in Diabetes—2016. Diabetes Care.
2016;39(S1):S1–112.
5. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic
control with diet, sulfonylurea, metformin, or
insulin in patients with type 2 diabetes mellitus:
progressive requirement for multiple therapies
(UKPDS49). JAMA. 1999;281(21):2005–12.
6. Kahn SE, Haffner SM, Heise MA, et al. Glycemic
durability of rosiglitazone, metformin, or glyburide
monotherapy. N Engl J Med.
2006;355(23):2427–43.
7. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect
of noninsulin antidiabetic drugs added to
metformin therapy on glycemic control, weight
gain, and hypoglycemia in type 2 diabetes. JAMA.
2010;303(14):1410–8.
8. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q.
Efficacy and safety of the dipeptidyl peptidase-4
inhibitor alogliptin in patients with type 2 diabetes
and inadequate glycemic control: a randomized,
double-blind, placebo-controlled study. Diabetes
Care. 2008;31:2315–7.
9. Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q.
Efficacy and safety of adding the dipeptidyl
peptidase-4 inhibitor alogliptin to metformin
therapy in patients with type 2 diabetes
inadequately controlled with metformin
monotherapy: a multicentre, randomised,
double-blind, placebo-controlled study. Int J Clin
Pract. 2009;63:46–55.
10. Bosi E, Ellis GC, Wilson CA, Fleck PR. Alogliptin as a
third oral antidiabetic drug in patients with type 2
diabetes and inadequate glycaemic control on
metformin and pioglitazone: a 52-week,
randomized, double-blind, active-controlled,
parallel-group study. Diabetes Obes Metab.
2011;13:1088–96.
11. Del Prato S, Camisasca R, Wilson C, Fleck P.
Durability of the efficacy and safety of alogliptin
compared with glipizide in type 2 diabetes mellitus:
a 2-year study. Diabetes Obes Metab.
2014;16:1239–46.
12. Del Prato S, Fleck P, Wilson C, Chaudhari P.
Comparison of alogliptin and glipizide for
composite endpoint of glycated haemoglobin
reduction, no hypoglycaemia and no weight gain
844 Diabetes Ther (2016) 7:825–845
in type 2 diabetes mellitus. Diabetes Obes Metab.
2016;18(6):623–7.
13. Palmer AJ, Roze S, Valentine WJ, et al. The CORE
Diabetes Model: projecting long-term clinical
outcomes, costs and costeffectiveness of
interventions in diabetes mellitus (types 1 and 2)
to support clinical and reimbursement
decision-making. Curr Med Res Opin.
2004;20(Suppl 1):S5–26.
14. Diabetes Control and Complications Trial Research
Group. The effect of intensive treatment of diabetes
on the development and progression of long-term
complications in insulin-dependent diabetes
mellitus. N Engl J Med. 1993;329(14):977–86.
15. D’Agostino RB, Russell MW, Huse DM, et al.
Primary and subsequent coronary risk appraisal:
new results from the Framingham study. Am Heart
J. 2000;139(2):272–81.
16. Alva ML, Gray A, Mihaylova B, Leal J, Holman R.
The impact of diabetes-related complications on
healthcare costs: new results from the UKPDS
(UKPDS 84). Diabet Med. 2015;32(4):459–66.
17. Clarke P, Gray A, Holman R. Estimating utility
values for health states of type 2 diabetic patients
using the EQ-5D (UKPDS 62). Med Decis Mak.
2002;22(4):340–9.
18. Personal Social Services Research Unit. Unit costs of
health and social care 2015. 2015. http://www.
pssru.ac.uk/project-pages/unit-costs/2015/index.php.
Accessed 23 Mar 2016.
19. Monthly Index of Medical Specialities. 2016. http://
www.mims.co.uk/. Accessed 23 Mar 2016.
20. Geng J, Yu H, Mao Y, Zhang P, Chen Y. Cost
effectiveness of dipeptidyl peptidase-4 inhibitors
for type 2 diabetes. Pharmacoeconomics.
2015;33(6):581–97.
21. Bergenheim K, Williams SA, Bergeson JG, Stern L,
Sriprasert M. US cost-effectiveness of saxagliptin in
type 2 diabetes mellitus. Am J Pharm Benefits.
2012;4(1):20–8.
22. Elgart JF, Caporale JE, Gonzalez L, Aiello E,
Waschbusch M, Gagliardino JJ. Treatment of type
2 diabetes with saxagliptin: a pharmacoeconomic
evaluation in Argentina. Health Econ Rev.
2013;3(1):1–9.
23. Erhardt W, Bergenheim K, Duprat-Lomon I,
McEwan P. Cost effectiveness of saxagliptin and
metformin versus sulfonylurea and metformin in
the treatment of type 2 diabetes mellitus in
Germany. Clin Drug Investig. 2012;32(3):189–202.
24. Granstro¨m O, Bergenheim K, McEwan P, Sennfa¨lt
K, Henriksson M. Cost-effectiveness of saxagliptin
(Onglyza) in type 2 diabetes in Sweden. Prim Care
Diabetes. 2012;6(2):127–36.
25. Schwarz B, Gouveia M, Chen J, et al.
Cost-effectiveness of sitagliptin-based treatment
regimens in European patients with type 2
diabetes and haemoglobin A1c above target on
metformin monotherapy. Diabetes Obes Metab.
2008;10(Suppl 1):43–55.
26. Nita ME, Eliaschewitz FG, Ribeiro E, et al.
Cost-effectiveness and budget impact of
saxagliptine as additional therapy to metformin
for the treatment of diabetes mellitus type 2 in the
Brazilian private health system. Rev Assoc Med Bras.
2012;58(3):294–301.
27. Grzeszczak W, Czupryniak L, Kolasa K, Sciborski C,
Lomon ID, McEwan P. The cost-effectiveness of
saxagliptin versus NPH insulin when used in
combination with other oral antidiabetes agents
in the treatment of type 2 diabetes mellitus in
Poland. Diabetes Technol Ther. 2012;14(1):65–73.
28. Klarenbach S, Cameron C, Singh S, Ur E.
Cost-effectiveness of second-line
antihyperglycemic therapy in patients with type 2
diabetes mellitus inadequately controlled on
metformin. CMAJ. 2011;183(16):E1213–20.
29. Teramachi H, Ohta H, Tachi T, et al.
Pharmacoeconomic analysis of DPP-4 inhibitors.
Pharmazie. 2013;68(11):909–15.
30. Office for National Statistics. Adult smoking habits
in Great Britain. London: Office for National
Statistics; 2013.
31. World Health Organization. Global Status Report
on Alcohol. Geneva: World Health Organization;
2004.
32. ACCORD Study Group. Effects of intensive
blood-pressure control in type 2 diabetes mellitus.
N Engl J Med. 2010;362(17):1575–85.
Diabetes Ther (2016) 7:825–845 845
